Veru (NASDAQ:VERU) Stock Rating Reaffirmed by Oppenheimer

Veru (NASDAQ:VERU - Get Free Report)'s stock had its "outperform" rating restated by stock analysts at Oppenheimer in a report issued on Monday, Benzinga reports. They currently have a $5.00 price objective on the stock, down from their prior price objective of $7.00. Oppenheimer's target price points to a potential upside of 226.80% from the company's previous close.

Other equities analysts have also recently issued research reports about the company. Raymond James started coverage on Veru in a research note on Thursday, March 28th. They issued an "outperform" rating and a $3.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $2.00 target price on shares of Veru in a research note on Thursday, February 8th.

Veru Price Performance

Shares of NASDAQ VERU traded up $0.01 during mid-day trading on Monday, reaching $1.53. 7,161,037 shares of the company traded hands, compared to its average volume of 2,312,067. Veru has a fifty-two week low of $0.36 and a fifty-two week high of $1.92. The stock has a fifty day simple moving average of $0.66 and a 200-day simple moving average of $0.74. The firm has a market cap of $223.96 million, a PE ratio of -1.81 and a beta of -0.22.

Institutional Investors Weigh In On Veru

Several hedge funds have recently modified their holdings of the business. Verition Fund Management LLC bought a new stake in Veru in the 4th quarter valued at $32,000. XTX Topco Ltd bought a new stake in shares of Veru in the second quarter valued at about $32,000. Segment Wealth Management LLC lifted its stake in shares of Veru by 50.0% in the third quarter. Segment Wealth Management LLC now owns 60,000 shares of the company's stock valued at $43,000 after buying an additional 20,000 shares during the period. Price T Rowe Associates Inc. MD grew its position in Veru by 150.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 63,300 shares of the company's stock worth $46,000 after buying an additional 38,000 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in Veru by 41.5% in the 1st quarter. Deutsche Bank AG now owns 43,396 shares of the company's stock valued at $50,000 after acquiring an additional 12,729 shares in the last quarter. 47.16% of the stock is owned by institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.